NUBEQA Treatment Option for Non-Metastatic Castration-Resistant Prostate Cancer
Dr. Matthew Smith, MD, Professor of Medicine at Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center discusses final data published in the “New England Journal of Medicine” (Sep 2020) from the Phase III ARAMIS trial for NUBEQA® (darolutamide) plus androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Matthew R. Smith, M.D., Ph.D. is Professor of Medicine at Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center. He received his MD and PhD degrees from Duke University School of Medicine. He completed Internal Medicine training at Brigham and Women’s Hospital, a Medical Oncology fellowship at Dana Farber Cancer Institute, and a postdoctoral fellowship at Massachusetts Institute of Technology. He has published extensively on the development of novel therapies,treatment and prevention of bone metastases, and survivorship in prostate cancer. He has authored more than 250 peer-reviewed articles on prostate cancer including manuscripts in New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Cancer, Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research. His research has been supported by competitive grants from the National Institutes of Health and the Prostate Cancer Foundation.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
